• Mashup Score: 16
    SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagy - 9 month(s) ago

    Objectives The protective role of sodium glucose cotransporter 2 (SGLT2) inhibitors in renal outcomes has been revealed by large cardiovascular outcome trials among patients with type 2 diabetes. However, the effect of SGLT2 inhibitors on lupus nephritis (LN) and its underlying mechanisms remain unknown. Methods We applied empagliflozin treatment to lupus-prone MRL/ lpr mice to explore the renal protective potential of SGLT2 inhibitors. An SGLT2 knockout monoclonal podocyte cell line was generated using the CRISPR/Cas9 system to examine the cellular and molecular mechanisms. Results In MRL/ lpr mice treated with empagliflozin, the levels of mouse anti-dsDNA IgG-specific antibodies, serum creatinine and proteinuria were markedly decreased. For renal pathology assessment, both the glomerular and tubulointerstitial damages were lessened by administration of empagliflozin. The levels of SGLT2 expression were increased and colocalised with decreased synaptopodin in the renal biopsy samples

    Source: ard.bmj.com
    Categories: Latest Headlines, Rheumatology
    Tweet Tweets with this article
    • Profile photo of ARD_BMJ
      ARD_BMJ

      Empagliflozin treatment to #lupus prone MRL/lpr mice to explore renal protective potential of #SGLT2 inhibitors. The SGLT2 inhibitor empagliflozin alleviated #podocyte injury by attenuating inflammation & enhanced autophagy by reducing mTORC1 activity. https://t.co/9EJDG0lOph https://t.co/zlaNSW5MJu

  • Mashup Score: 2
    Top news June 2023: FDA approvals, updates from NLA and more - 10 month(s) ago

    Healio | Cardiology Today has compiled a list of the top headlines in cardiology of June 2023.Readers were most interested in the FDA approvals of colchicine 0.5 mg, IV ferric carboxymaltose and mavacamten for various CV indications; updates from the National Lipid Association Scientific Sessions and Heart in Diabetes CME Conference; and more.

    Source: www.healio.com
    Categories: Cardiology News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ACCmediacenter
      ACCmediacenter

      A #JACC study found that #SGLT2 inhibitors reduce the risk of CV death and #HeartFailure events in patients with heart failure, #diabetes and chronic kidney disease. https://t.co/66QuRG6Pys @CardiologyToday

  • Mashup Score: 1
    Meta-analysis confirms benefits of SGLT2 inhibitors in various high-risk populations - 11 month(s) ago

    SGLT2 inhibitors reduce risk for CV death and HF events in patients with any or multiple of HF, type 2 diabetes and chronic kidney disease, according to a meta-analysis published in the Journal of the American College of Cardiology.The researchers conducted a meta-analysis of 13 trials of SGLT2 inhibitors vs. placebo in 90,413 patients with HF, type 2 diabetes and/or chronic kidney disease (CKD).

    Source: www.healio.com
    Categories: Cardiology News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ACCmediacenter
      ACCmediacenter

      According to a meta-analysis in #JACC, #SGLT2 inhibitors decrease the risk of CV death and #HeartFailure hospitalization in high-risk patients. @CardiologyToday covers the findings here: https://t.co/TaQXfHSgve

  • Mashup Score: 0
    SGLT2 inhibitors may reduce cancer risks among adults with diabetes - 11 month(s) ago

    Adults with diabetes who use SGLT2 inhibitors have lower risks for developing most types of cancer compared with nonusers, though the risk for pancreatic cancer is higher among SGLT2 users, according to data from researchers in Taiwan. “Recently, novel antidiabetic agents with SGLT2 inhibitors were introduced and several pluripotent effects were proposed,” Wei-Syun Hu, MD, PhD,

    Source: www.healio.com
    Categories: Endocrinology, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of EndocrineToday
      EndocrineToday

      Adults with #diabetes who use #SGLT2 inhibitors have a lower risk for developing most types of #cancer than those who do not use an SGLT2, according to findings from a study conducted in Taiwan. @research_cmu @ElsevierConnect https://t.co/aIzW82HqOA

  • Mashup Score: 0
    SGLT2 inhibition could lower stroke risk in those with diabetes plus atrial fibrillation - 11 month(s) ago

    SGLT2 inhibition was associated with reduced 5-year risk for stroke among patients with concomitant atrial fibrillation and diabetes, according to a study in the Journal of the American Heart Association. “From the animal studies, SGLT2 inhibitors could decrease oxidative stress in cardiomyocytes, reverse myocardial remodeling and reduce electronic alterations. These pleiotropic effects of

    Source: www.healio.com
    Categories: Cardiology News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of CardiologyToday
      CardiologyToday

      #SGLT2 inhibition was associated with reduced 5-year risk for stroke among patients with concomitant #AFib and diabetes @JAHA_AHA @EndocrineToday #cardiotwitter https://t.co/gVSUHGvwgl

  • Mashup Score: 3
    Empagliflozin HF benefits extend across spectrum of kidney disease - 1 year(s) ago

    Kidney disease does not influence the benefits of the SGLT2 inhibitor empagliflozin on major HF events, even in patients at high renal risk, according to a new analysis of the EMPEROR-Pooled study. “In indicated patients, SGLT2 inhibitors should be used early in the disease process to modify cardiorenal risk and improve long-term outcomes,” Healio | Cardiology Today Editorial Board

    Source: www.healio.com
    Categories: Cardiology News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ACCmediacenter
      ACCmediacenter

      According to new findings in #JACC, kidney disease does not impact the benefits of the #SGLT2 empagliflozin on major #HeartFailure events. @CardiologyToday reports on the study: https://t.co/K0iADKHckh

Load More